by MIT Technology Review by Cassandra Willyard — Just last week Microsoft announced that it had partnered with a digital pathology company, Paige, in order to build the world’s largest image-based AI model for identifying cancer. This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here. I just had a birthday, and you know what that means—I’m newly eligible for a screening colonoscopy. (#milestones!). I’ve been thinking about cancer screening a lot recently, because I’ve seen a handful of headlines in the past few months about how AI will revolutionize cancer detection. Just last week Microsoft announced that it had partnered with a digital pathology company, Paige, in order to build the world’s largest image-based AI model for identifying cancer. The training data set for the algorithm contains 4 million images. “This is sort of a groundbreaking, land-on-the-moon kind of moment for cancer care,” Paige CEO Andy Moye told CNBC.
Well, it might be. Last month, results from the first clinical trial of AI-supported breast cancer screening came out. The researchers compared two methods for reading a mammogram: a standard reading by two independent radiologists, and a system that used a single radiologist and an AI to assign patients a numerical cancer risk score from 1 to 10. In the latter group, those who scored a 10—the highest risk—then had their images read by two radiologists. The AI-supported model reduced workload by 44% and detected 20% more cancers. That sounds like a good thing. In theory, catching cancers earlier should make them easier to treat, saving lives. But that’s not always what the data shows. A study published in late August combed the literature for randomized clinical trials that compared mortality (from any cause, not just cancer) in two groups: people who underwent cancer screening and people who did not. For most common types of cancer screening, they found no significant difference. The exception was sigmoidoscopy, a type of colon cancer screening that involves visualizing only the lower portion of the colon.